Wockhardt has received an approval from the Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) for Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults. Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP including those caused by multi-drug resistant (MDR) pathogens. The approval follows a favourable recommendation for manufacture and marketing of Nafithromycin from the Subject Expert Committee (SEC) of CDSCO.
Wockhardt plans to launch Miqnaf in the Indian market in coming few months. Over the period of 25 years, Wockhardt has focused its drug discovery efforts in the area of discovering novel antibiotics for multi-drug resistant infections. This has resulted in a portfolio of 6 products at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA.
Wockhardt is a research based Global Pharmaceutical and Biotech company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1770.10 |
Dr. Reddys Lab | 1151.25 |
Cipla | 1495.15 |
Lupin | 2094.50 |
Zydus Lifesciences | 901.05 |
View more.. |